TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

ACER

OncologyImmunologyRespiratory
Pharma

ACER is a pharmaceutical company focused on Oncology, Immunology, Respiratory. Key products include OLPRUVA.

2022
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

OLPRUVA
sodium phenylbutyrate
2 indications · 2022

Recent Activity

OLPRUVA 2025-10-10
Efficacy
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 91%
0 drugs Phase 3: 7 Phase 2: 9 Phase 1: 7
Immunology 3%
0 drugs Phase 2: 1
Respiratory 3%
0 drugs Phase 2: 1
Gastroenterology 2%
0 drugs Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Novartis big-pharma
Oncology, Immunology, Respiratory
Gilead Sciences biotech
Oncology, Immunology, Gastroenterology, Respiratory
GSK big-pharma
Respiratory, Oncology, Immunology
Sanofi big-pharma
Oncology, Immunology, Respiratory